BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 37515128)

  • 1. Recent Developments in Human Papillomavirus (HPV) Vaccinology.
    Williamson AL
    Viruses; 2023 Jun; 15(7):. PubMed ID: 37515128
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors.
    Arbyn M; Xu L; Simoens C; Martin-Hirsch PP
    Cochrane Database Syst Rev; 2018 May; 5(5):CD009069. PubMed ID: 29740819
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP).
    Markowitz LE; Dunne EF; Saraiya M; Lawson HW; Chesson H; Unger ER; ;
    MMWR Recomm Rep; 2007 Mar; 56(RR-2):1-24. PubMed ID: 17380109
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Primary prevention of cervical cancer: prophylactic human papillomavirus vaccines.
    Mandic A
    J BUON; 2012; 17(3):422-7. PubMed ID: 23033276
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Population-level impact of the bivalent, quadrivalent, and nonavalent human papillomavirus vaccines: a model-based analysis.
    Van de Velde N; Boily MC; Drolet M; Franco EL; Mayrand MH; Kliewer EV; Coutlée F; Laprise JF; Malagón T; Brisson M
    J Natl Cancer Inst; 2012 Nov; 104(22):1712-23. PubMed ID: 23104323
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical trials of human papillomavirus vaccines and beyond.
    Lehtinen M; Dillner J
    Nat Rev Clin Oncol; 2013 Jul; 10(7):400-10. PubMed ID: 23736648
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunogenicity, efficacy, and safety of human papillomavirus vaccine: Data from China.
    Li M; Zhao C; Zhao Y; Li J; Wei L
    Front Immunol; 2023; 14():1112750. PubMed ID: 36993948
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Human papillomavirus vaccines].
    Brun JL
    J Gynecol Obstet Biol Reprod (Paris); 2008 Feb; 37 Suppl 1():S155-66. PubMed ID: 18187268
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Human papillomavirus nonavalent vaccine. Update 2017].
    Bosch FX; Moreno D; Redondo E; Torné A
    Semergen; 2017; 43(4):265-276. PubMed ID: 28549940
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Use of Both Therapeutic and Prophylactic Vaccines in the Therapy of Papillomavirus Disease.
    Garbuglia AR; Lapa D; Sias C; Capobianchi MR; Del Porto P
    Front Immunol; 2020; 11():188. PubMed ID: 32133000
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potential impact of a nonavalent HPV vaccine on the occurrence of HPV-related diseases in France.
    Riethmuller D; Jacquard AC; Lacau St Guily J; Aubin F; Carcopino X; Pradat P; Dahlab A; Prétet JL
    BMC Public Health; 2015 May; 15():453. PubMed ID: 25934423
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A review of prophylactic human papillomavirus vaccines: recommendations and monitoring in the US.
    Dunne EF; Datta SD; E Markowitz L
    Cancer; 2008 Nov; 113(10 Suppl):2995-3003. PubMed ID: 18980283
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Human papillomavirus vaccination. Consensus Conference in pediatric age].
    Bartolozzi G; Bona G; Ciofi M; De Martino M; Di Pietro P; Duse M; Esposito S; Gasparini R; Mariani L; Marostica G; Paravati F; Plebani A; Principi N; Zuccotti GV; Tovo PA
    Minerva Pediatr; 2007 Jun; 59(3):165-82. PubMed ID: 17519861
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Post-marketing surveillance study of the safety of the HPV-16/18 vaccine in Korea (2017-2021).
    Eun BW; Bahar E; Xavier S; Kim H; Borys D
    Hum Vaccin Immunother; 2023 Dec; 19(1):2184756. PubMed ID: 36896702
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Human papillomavirus prophylactic vaccines: stakes and perspectives].
    Hantz S; Alain S; Denis F
    Gynecol Obstet Fertil; 2006; 34(7-8):647-55. PubMed ID: 16807045
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The human papillomavirus vaccines.
    Ljubojević S
    Acta Dermatovenerol Croat; 2006; 14(3):208. PubMed ID: 17010274
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Vaccination against human papillomavirus. Implementation and efficacy against cervical cancer control].
    Bégué P; Henrion R; Blanc B; Girard M; Sancho-Garnier H
    Bull Acad Natl Med; 2007 Dec; 191(9):1805-16; discussion 1816-7. PubMed ID: 18663976
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Developments in L2-based human papillomavirus (HPV) vaccines.
    Schellenbacher C; Roden RBS; Kirnbauer R
    Virus Res; 2017 Mar; 231():166-175. PubMed ID: 27889616
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical and economic impact of school-based nonavalent human papillomavirus vaccine on women in Singapore: a transmission dynamic mathematical model analysis.
    Tay SK; Hsu TY; Pavelyev A; Walia A; Kulkarni AS
    BJOG; 2018 Mar; 125(4):478-486. PubMed ID: 29266694
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevention of human papillomavirus (HPV)-related tumors in people living with human immunodeficiency virus (HIV).
    Poljak M; Šterbenc A; Lunar MM
    Expert Rev Anti Infect Ther; 2017 Nov; 15(11):987-999. PubMed ID: 29027811
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.